Table 1.

Baseline characteristics of study participants by quartiles of baseline plasma FGF-23 concentrations

FGF-23 concentrationsQ1 ≤216 RU/mlQ2 217–380 RU/mlQ3 381–945 RU/mlQ4 >946 RU/mlP Value for Trend
Age (years)72 ± 1170 ± 1068 ± 1165 ± 11<0.0001
Sex (% Male)98.598.997.898.20.52
Race (% African American)34.225.027.419.00.0003
Diabetes (%)45.154.762.857.30.0009
Hypertension (%)96.794.696.498.20.22
CVD (%)49.159.162.857.00.01
Charlson score4.5 ± 2.25.1 ± 2.25.4 ± 2.25.2 ± 2.1<0.0001
Current smoking (%)10.518.817.027.0<0.0001
Medications (%)
    ACEI/ARB44.740.641.637.60.13
    CCB60.067.468.262.80.48
    Beta-blocker53.162.361.760.60.09
    Lipid-lowering54.257.659.955.10.71
    Sevelamer2.51.83.36.20.01
BMI (kg/m2)26.8 ± 4.227.6 ± 4.528.6 ± 5.228.7 ± 5.1<0.0001
SBP (mmHg)140 ± 22143 ± 23146 ± 23144 ± 240.007
DBP (mmHg)72 ± 1373 ± 1373 ± 1274 ± 130.11
MDRD-GFR (ml/min/1.73m2)23 ± 620 ± 616 ± 515 ± 5<0.0001
Hemoglobin (g/dl)12.3 ± 1.612.1 ± 1.611.6 ± 1.611.5 ± 1.8<0.0001
Albumin (mg/dl)4.2 ± 0.54.2 ± 0.54.0 ± 0.54.0 ± 0.50.0001
Calcium (mg/dl)9.0 ± 0.58.9 ± 0.78.9 ± 0.78.9 ± 0.90.21
Phosphorus (mg/dl)3.8 ± 0.84.1 ± 0.94.5 ± 1.65.1 ± 1.4<0.0001
LDL-C (mg/dl)97 ± 3395 ± 3093 ± 3494 ± 340.27
HDL-C (mg/dl)45 ± 1743 ± 1542 ± 1440 ± 13<0.0001
25(OH)D (ng/ml)21 ± 1121 ± 1020 ± 1021 ± 110.70
1,25(OH)2D (pg/ml)25 ± 1122 ± 1018 ± 1019 ± 9<0.0001
iPTH (pg/ml)122 ± 77170 ± 109223 ± 160269 ± 224<0.0001
  • Values are expressed as means ± standard deviation unless otherwise specified. CVD, cardiovascular disease; BMI, body mass index; ACE Inhibitor, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; GFR, glomerular filtration rate; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; iPTH, intact parathyroid hormone.